According to MSB’s announcement the 44% represented patients with ischemic cardiomyopathy and showed an improvement in that subgroup analysis. That’s actially another gripe I have - there’s no mention of the results from the 56% of patients with non-ischemic cardiomyopathy. Did they do worse with MSCs? And is it connected to the “high rate of pump thrombosis” (an explanation given to us without any qualification)?
So all we have an abstract written by the NHC published by the AHA and a statement from MSB with extra data - they obviously have access to the full article.
i accept that I can’t say for sure that the CCF trial won’t succeed but equally no one can say it wil. Today’s results don’t fill me with confidence though - I want to read the full article rather than just an abstract.
Let’s not get excited about stem cells and GI bleeding, page-3
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.065(4.69%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.50 | $1.38 | $7.016M | 4.856M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10425 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 44243 | 5 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |